J-y Pierga
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 25, 2026
Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.
Journal: ESMO open
Published: December 10, 2025
Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.
Journal: ESMO open
Published: November 11, 2025
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 01, 2025
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06.
Journal: ESMO open
Published: January 31, 2025
Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 02, 2024
Blood tumor load: combining biomarkers to increase the proportion of informative patients.
Journal: ESMO open
Published: August 13, 2024
A Therapeutic Challenge: Chemo-refractory Non-metastatic Inflammatory Breast Cancers.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: December 10, 2021
Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
Journal: Breast cancer research and treatment
Published: April 24, 2019
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 13, 2018
Last Updated: 09/26/2026